Skip to main content

Main menu

  • Home
  • About
    • About CBM
    • Editorial Board
    • Announcement
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Other Publications
    • cbm

User menu

  • My alerts

Search

  • Advanced search
Cancer Biology & Medicine
  • Other Publications
    • cbm
  • My alerts
Cancer Biology & Medicine

Advanced Search

 

  • Home
  • About
    • About CBM
    • Editorial Board
    • Announcement
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Follow cbm on Twitter
  • Visit cbm on Facebook
Review ArticleReview

The advanced development of molecular targeted therapy for hepatocellular carcinoma

Tao Yan, Lingxiang Yu, Ning Zhang, Caiyun Peng, Guodong Su, Yi Jing, Linzhi Zhang, Tong Wu, Jiamin Cheng, Qian Guo, Xiaoliang Shi and Yinying Lu
Cancer Biology & Medicine June 2022, 19 (6) 802-817; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0661
Tao Yan
1Comprehensive Liver Cancer Center, the 5th Medical Center of Chinese PLA General Hospital, Beijing 100039, China
2The Second School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lingxiang Yu
3The Second Department of Hepatobiliary Surgery, Senior Department of Hepatology, the 5th Medical Center of Chinese PLA General Hospital, Beijing 100039, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ning Zhang
1Comprehensive Liver Cancer Center, the 5th Medical Center of Chinese PLA General Hospital, Beijing 100039, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caiyun Peng
1Comprehensive Liver Cancer Center, the 5th Medical Center of Chinese PLA General Hospital, Beijing 100039, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guodong Su
1Comprehensive Liver Cancer Center, the 5th Medical Center of Chinese PLA General Hospital, Beijing 100039, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yi Jing
1Comprehensive Liver Cancer Center, the 5th Medical Center of Chinese PLA General Hospital, Beijing 100039, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Linzhi Zhang
1Comprehensive Liver Cancer Center, the 5th Medical Center of Chinese PLA General Hospital, Beijing 100039, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tong Wu
1Comprehensive Liver Cancer Center, the 5th Medical Center of Chinese PLA General Hospital, Beijing 100039, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jiamin Cheng
1Comprehensive Liver Cancer Center, the 5th Medical Center of Chinese PLA General Hospital, Beijing 100039, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qian Guo
2The Second School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaoliang Shi
4Shanghai OrigiMed Co., Ltd., Shanghai 201112, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Xiaoliang Shi
  • For correspondence: luyinying1973{at}163.com shixiaoliang{at}origimed.com
Yinying Lu
1Comprehensive Liver Cancer Center, the 5th Medical Center of Chinese PLA General Hospital, Beijing 100039, China
2The Second School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China
5National Clinical Medical Research Center for Infectious Diseases, the 5th Medical Center of Chinese PLA General Hospital, Beijing 100039, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yinying Lu
  • For correspondence: luyinying1973{at}163.com shixiaoliang{at}origimed.com
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Patterns of targeted therapy, immunotherapy, and combined immunotherapy in HCC.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1

    Patterns of targeted therapy, immunotherapy, and combined immunotherapy in HCC.

  • Development of HCC immunotherapy. Ellipses indicate approval by the US FDA.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2

    Development of HCC immunotherapy. Ellipses indicate approval by the US FDA.

Tables

  • Figures
    • View popup
    Table 1

    Molecular classifications for HCC

    OmicsPatient No.HCC subtypeMeaningReference
    Genomic300C1–C6Clinical implications and association with prognosisFujimoto et al., 201633
    Genomic243MSig 1–MSig 6Design of clinical trials for targeted therapySchulze et al., 201532
    Transcriptome91A, BPrediction of HCC clinical outcome at the time of diagnosisLee et al., 200428
    Transcriptome123G1–G6Identification of patients who may benefit from targeted therapiesBoyault et al., 200729
    Transcriptome603S1–S3Guidance for the design of future clinical trials aimed at targeting agents to distinct patient populationsHoshida et al., 200930
    Transcriptome231C1–C3Prediction of the prognosis of patients with HCC and prospective therapiesYang et al., 202031
    Proteome159S-Mb, S-Pf, S-MeProvision of unique therapeutic opportunitiesGao et al., 201934
    Proteome110S-I, S-II, S-IIIProvision of insight into tumor biology and opportunities for personalized targeted therapiesJiang et al., 201935
    • View popup
    Table 2

    Targeted therapy in HCC

    DrugControlLineStatusReference
    SorafenibPlaceboFirst lineApproved (US FDA, NMPA)Llovet et al., 200897; Cheng et al., 200998
    LenvatinibSorafenibFirst lineApproved (US FDA, NMPA)Kudo et al., 2018115
    SunitinibSorafenibFirst lineFailedCheng et al., 2013112
    LinifanibSorafenibFirst lineFailedCainap et al., 2015113
    DovotinibSorafenibFirst lineFailedCheng et al., 2016144
    DonafenibSorafenibFirst lineApproved (NMPA)Bi et al., 2020119
    ApatinibSorafenibSecond lineApproved (NMPA)He et al., 2020134
    RegorafenibNon-candidate groupsSecond lineApproved (US FDA, NMPA)Kuzuya et al., 2019123; Teufel et al., 2019122
    CabozantinibNon-candidate groupsSecond lineApproved (US FDA)Kuzuya et al., 2019123; Abou-Alfa et al., 2018126
    RamucirumabPlaceboSecond lineApproved (US FDA, NMPA; ongoing)Zhu et al., 2015130; Kudo et al., 2020132
PreviousNext
Back to top

In this issue

Cancer Biology & Medicine: 19 (6)
Cancer Biology & Medicine
Vol. 19, Issue 6
15 Jun 2022
  • Table of Contents
  • Index by author
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on Cancer Biology & Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The advanced development of molecular targeted therapy for hepatocellular carcinoma
(Your Name) has sent you a message from Cancer Biology & Medicine
(Your Name) thought you would like to see the Cancer Biology & Medicine web site.
Citation Tools
The advanced development of molecular targeted therapy for hepatocellular carcinoma
Tao Yan, Lingxiang Yu, Ning Zhang, Caiyun Peng, Guodong Su, Yi Jing, Linzhi Zhang, Tong Wu, Jiamin Cheng, Qian Guo, Xiaoliang Shi, Yinying Lu
Cancer Biology & Medicine Jun 2022, 19 (6) 802-817; DOI: 10.20892/j.issn.2095-3941.2021.0661

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The advanced development of molecular targeted therapy for hepatocellular carcinoma
Tao Yan, Lingxiang Yu, Ning Zhang, Caiyun Peng, Guodong Su, Yi Jing, Linzhi Zhang, Tong Wu, Jiamin Cheng, Qian Guo, Xiaoliang Shi, Yinying Lu
Cancer Biology & Medicine Jun 2022, 19 (6) 802-817; DOI: 10.20892/j.issn.2095-3941.2021.0661
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Early diagnosis and treatment of HCC
    • Biomarkers for HCC diagnosis and prognostication
    • Advanced progress in targeted therapy for HCC
    • Advanced progress in immunotherapy in HCC
    • Conclusions and perspectives
    • Grant support
    • Conflict of interest statement
    • Author contributions
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • Angiogenesis in hepatocellular carcinoma: mechanisms and anti-angiogenic therapies
  • Google Scholar

More in this TOC Section

  • Treatment implications of T cell DNA damage in anti-tumor immunity
  • Non-coding RNA delivery via lipid nanoparticles: a novel strategy for cancer immunotherapy
  • Pyroptosis in cancer: a dual regulator of tumor cell fate and immune activation
Show more Review

Similar Articles

Keywords

  • Hepatocellular carcinoma
  • precision medicine
  • liquid biopsy
  • targeted therapy
  • immunotherapy

Navigate

  • Home
  • Current Issue

More Information

  • About CBM
  • About CACA
  • About TMUCIH
  • Editorial Board
  • Subscription

For Authors

  • Instructions for authors
  • Journal Policies
  • Submit a Manuscript

Journal Services

  • Email Alerts
  • Facebook
  • RSS Feeds
  • Twitter

 

© 2026 Cancer Biology & Medicine

Powered by HighWire